Product Description
An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon oral administration, CDK2 inhibitor BG-68501 selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk2-inhibitor-bg-68501)
Mechanisms of Action: CDK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BeOne Medicines
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Israel, Moldova, New Zealand, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Bladder Cancer|Endometrial Cancer|Esophageal Cancer|Gastrointestinal Cancer|Ovarian Cancer|Prostate Cancer|Small Cell Lung Cancer|Triple Negative Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06257264 |
BG-68501-101 | P1 |
Active, not recruiting |
Gastrointestinal Cancer|Bladder Cancer|Esophageal Cancer|Endometrial Cancer|Ovarian Cancer|Small Cell Lung Cancer|Prostate Cancer|Triple Negative Breast Cancer |
2026-08-31 |
12% |
2026-06-06 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/02/2025 |
News Article |
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 |
|
05/22/2025 |
News Article |
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors |
|
04/22/2025 |
News Article |
Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636 |
|
02/27/2025 |
News Article |
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates |